Cerity Partners LLC Takes Position in Nkarta, Inc. (NASDAQ:NKTX)

Cerity Partners LLC purchased a new position in shares of Nkarta, Inc. (NASDAQ:NKTX) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 29,770 shares of the company’s stock, valued at approximately $55,000.

Several other institutional investors and hedge funds also recently made changes to their positions in NKTX. Wealth Enhancement Advisory Services LLC bought a new stake in Nkarta during the 1st quarter worth approximately $32,000. Wellington Management Group LLP lifted its holdings in shares of Nkarta by 4.1% during the fourth quarter. Wellington Management Group LLP now owns 225,224 shares of the company’s stock worth $561,000 after purchasing an additional 8,883 shares during the period. Bank of America Corp DE grew its stake in shares of Nkarta by 110.1% in the fourth quarter. Bank of America Corp DE now owns 380,444 shares of the company’s stock worth $947,000 after purchasing an additional 199,345 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Nkarta by 138.7% in the fourth quarter. JPMorgan Chase & Co. now owns 2,537,922 shares of the company’s stock worth $6,319,000 after purchasing an additional 1,474,560 shares during the last quarter. Finally, Deutsche Bank AG increased its holdings in Nkarta by 26.1% in the fourth quarter. Deutsche Bank AG now owns 43,157 shares of the company’s stock valued at $107,000 after purchasing an additional 8,946 shares during the period. Institutional investors and hedge funds own 80.54% of the company’s stock.

Analyst Ratings Changes

NKTX has been the topic of several recent research reports. Mizuho cut their target price on Nkarta from $16.00 to $14.00 and set an “outperform” rating on the stock in a report on Tuesday, June 10th. William Blair reissued a “market perform” rating on shares of Nkarta in a research report on Thursday, May 15th. Finally, Needham & Company LLC lowered their price target on shares of Nkarta from $11.00 to $10.00 and set a “buy” rating for the company in a report on Thursday, May 15th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $14.33.

Nkarta Price Performance

Shares of NKTX opened at $2.18 on Thursday. Nkarta, Inc. has a one year low of $1.31 and a one year high of $6.74. The company has a market cap of $154.69 million, a PE ratio of -1.44 and a beta of 0.70. The stock has a 50-day moving average of $1.86 and a 200-day moving average of $1.91.

Nkarta (NASDAQ:NKTX) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.43) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.01. Analysts expect that Nkarta, Inc. will post -1.7 EPS for the current fiscal year.

Nkarta Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.